Loading
The larger follow-on Chinese study validating a blood test for several gynaecological cancers.
PERCEIVE-II (NCT06001099) is an observational study sponsored by Fudan University with Guangzhou Burning Rock Dx Co., Ltd. It validates combined methylation, mutation and microRNA assays for early detection of gynaecological cancers.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 29 September 2023), with an estimated 2,935 participants, a start on 22 February 2023 and primary completion expected on 30 June 2024.
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/